Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.

@article{Hanson2006EfficacyAS,
  title={Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.},
  author={Peter D. Hanson and Kenneth C Brooks and Jerry L. Case and Michael G. Conzemius and Wanda Gordon and James Schuessler and Bert A Shelley and Roger L. Sifferman and Marlene D Drag and Roberto Alva and Laura Hannah Bell and Davida Romano and Candis Fleishman},
  journal={Veterinary therapeutics : research in applied veterinary medicine},
  year={2006},
  volume={7 2},
  pages={127-40}
}
A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days. Veterinary examinations were performed on approximately days 0 (visit 1), 14 (visit 2), and 29 (visit 3). Based on defined noninferiority criteria, firocoxib and etodolac were comparable. Based on the magnitude of the change from baseline, improvement with firocoxib was significantly greater than with etodolac for lameness at a trot… CONTINUE READING